Literature DB >> 21492935

Expression of NG2 antigen in MLL-rearranged acute leukemias: how complex does it get?

Pablo Menendez, Clara Bueno.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21492935     DOI： 10.1016/j.leukres.2011.03.015

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  6 in total

Review 1.  Revisiting the biology of infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia.

Authors:  Alejandra Sanjuan-Pla; Clara Bueno; Cristina Prieto; Pamela Acha; Ronald W Stam; Rolf Marschalek; Pablo Menéndez
Journal:  Blood       Date:  2015-10-13       Impact factor: 22.113

2.  Novel Diagnostic and Therapeutic Options for KMT2A-Rearranged Acute Leukemias.

Authors:  Bruno A Lopes; Caroline Pires Poubel; Cristiane Esteves Teixeira; Aurélie Caye-Eude; Hélène Cavé; Claus Meyer; Rolf Marschalek; Mariana Boroni; Mariana Emerenciano
Journal:  Front Pharmacol       Date:  2022-06-06       Impact factor: 5.988

3.  NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL.

Authors:  C Prieto; B López-Millán; H Roca-Ho; R W Stam; D Romero-Moya; F J Rodríguez-Baena; A Sanjuan-Pla; V Ayllón; M Ramírez; M Bardini; P De Lorenzo; M G Valsecchi; M Stanulla; M Iglesias; P Ballerini; Á M Carcaboso; J Mora; F Locatelli; A Bertaina; L Padilla; Juan Carlos Rodríguez-Manzaneque; C Bueno; P Menéndez
Journal:  Leukemia       Date:  2017-09-25       Impact factor: 11.528

4.  NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia.

Authors:  Belen Lopez-Millan; Diego Sanchéz-Martínez; Heleia Roca-Ho; Francisco Gutiérrez-Agüera; Oscar Molina; Rafael Diaz de la Guardia; Raúl Torres-Ruiz; Jose Luís Fuster; Paola Ballerini; Ute Suessbier; Cesar Nombela-Arrieta; Clara Bueno; Pablo Menéndez
Journal:  Leukemia       Date:  2019-01-11       Impact factor: 11.528

Review 5.  Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments.

Authors:  Xinjie Xu; Shengkang Huang; Xinyi Xiao; Qihang Sun; Xiaoqian Liang; Sifei Chen; Zijing Zhao; Zhaochang Huo; Sanfang Tu; Yuhua Li
Journal:  Front Immunol       Date:  2021-02-10       Impact factor: 7.561

Review 6.  Theranostic impact of NG2/CSPG4 proteoglycan in cancer.

Authors:  Pier Andrea Nicolosi; Alice Dallatomasina; Roberto Perris
Journal:  Theranostics       Date:  2015-02-15       Impact factor: 11.556
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.